Dexamethasone-Eluting Cochlear Implant Electrode

Hearing Loss, Sensorineural Clinical Trial

— CIDEX  

Official title:

Dexamethasone-Eluting Cochlear Implant Electrode (CIDEXEL): A First in Human Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04450290
• Other study ID #: MED-EL_CRD_2014_02
• Status: Completed
• Phase: N/A
• Start date: June 30, 2020
• Est. completion date: May 5, 2022

Study information

• Verified date: May 2022
• Source: MED-EL Elektromedizinische Geräte GesmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.

The aim of this clinical investigation is to obtain a first experience in use of the investigational device in the adult clinical population, and to initially assess tools, techniques and performance outcome measures that may be considered in future clinical studies of similar devices.

Description:

The principal objective of this study is to exploratively investigate the safety profile of the device which will be evaluated through the analysis of adverse events during the follow-up period. For the study to be considered a success, the results of the adverse event analysis shall never cause an unbalanced risk vs. benefit assessment.

The secondary objectives of this study aim at investigating the usefulness of possible outcome measures in evaluating the performance of the device.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: May 5, 2022
• Est. primary completion date: May 5, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Minimum age of eighteen (18) years at time of enrolment.

• Severe to profound sensorineural hearing loss on the ipsilateral ear.

• A functional auditory nerve in the ear to be implanted.

• Subjects reporting to having used an optimally fit hearing aids for a minimum of three months before the decision that a cochlear implant (CI) is the preferential option.

• Cochlea anatomy compatible with the insertion of a +FLEX28 electrode array.

• Compatibility with a soft surgery approach as per clinical practice at the site.

• Post-lingual hearing impairment.

• Subject fulfilling indication criteria for a CI according to the local professional standards, as reported by the implanting surgeon.

• General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study and realistic expectations, as deemed appropriate by the implanting surgeon.

• Signed and dated informed consent before the start of any study-specific procedure.

Exclusion Criteria:

• Lack of compliance with any inclusion criterion.

• Previously having received a cochlear implant on the ear chosen for placing the IMD (Investigational Medical Device).

• Evidence of ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array or might cause increased risk of infection (e.g. dysplastic cochlea), as confirmed by medical examination and/or as per CT/MRT (Computed Tomography/Magnetic Resonance Tomography).

• Evidence of anatomic abnormalities that would prevent appropriate placement of the stimulator housing in the bone of the skull.

• Evidence of otosclerosis.

• Known allergic reaction or intolerance to the materials used in the implant (including medical grade silicone, platinum, iridium, parylene c, dexamethasone).

• Known absence of cochlear development or if the cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway.

• Evidence of active external or middle ear infection or history of recurrent middle ear infection in the ear to be implanted.

• Evidence of perforated tympanic membrane in the ear to be implanted.

• Patient reporting immunosuppressive therapy or corticosteroids therapy in the 4 weeks before enrolment.

• Evidence of concomitant use of medicinal substances that, in the opinion of the investigator, could alter the therapeutic efficacy of dexamethasone.

• Unwillingness or inability of the candidate to comply with all investigational requirements.

• Evidence of medical contraindications to surgery of the middle and inner ear and anaesthesia.

• Additional disabilities that would prevent or restrict participation in the audiological and medical evaluations required of the clinical investigation.

Related Conditions & MeSH terms

• Deafness
• Hearing Loss
• Hearing Loss, Sensorineural
• Sensorineural Hearing Loss

Intervention

Device:
• CIDEXEL implant
The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.

Locations

Country	Name	City	State
Germany	MHH - Medizinische Hochschule Hannover	Hannover

Sponsors (1)

Lead Sponsor	Collaborator
MED-EL Elektromedizinische Geräte GesmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events	Safety profile of the device which will be evaluated through the analysis of adverse events	10 months
Secondary	IFT (Impedance Field Telemetry) - impedance	Impedance Field Telemetry and derived values	10 months
Secondary	Electrically Evoked Compound Action Potential	Electrically Evoked Compound Action Potential and derived values	10 months
Secondary	MCL (Maximum Comfortable Loudness)	Maximum Comfortable Loudness Levels and Thresholds	10 months
Secondary	THR (Threshold)	Thresholds	10 months
Secondary	PTA (Pure Tone Audiometry) Audiometrical values	Results from PTA assessment	10 months
Secondary	Hearing Preservation rate	Rate of Hearing Preservation according to Skarzynski et al.	10 months
Secondary	HSM (Hochmair-Schulz-Moser Sentence) Test	Speech test in noise	10 months
Secondary	Questionnaire	Surgical feedback questionnaire	10 months